Healthcare entity
Every one of those 1 sits in a single category, market-trends. MAV/06 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Healthcare story that mention GC Biopharma, all published on March 11, 2026.
Last mentioned: Mar 11, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. MAV/06 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Healthcare story that mention GC Biopharma, all published on March 11, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 8 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GC Biopharma. Shared-story counts are live from our verified record — not editorial picks.
GC Biopharma has published a landmark review paper detailing three decades of clinical and real-world data for its proprietary MAV/06 varicella vaccine strain. The publication underscores the strain's long-term safety and efficacy, positioning it as a primary global alternative to the widely used Oka strain.
Source: manilatimes.net · thailand-business-news.com
GC Biopharma is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
